La cadena de opciones muestra datos clave de las opciones de acciones de Mural Oncology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Mural Oncology..

Mural Oncology (NASDAQ:MURA) Bolsa, Cadena de Opciones

Mural Oncology

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology PLC

Murakami Corp

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments PLC

MURATA MFG INC ORD by Murata Manufacturing Inc.

Murata Manufacturing Co Ltd

MURATA MFG INC UNSP/ADR by Murata Manufacturing Inc.

News

Tencent Music Enter Gr Q4 Adj EPADS $0.20, Sales $1.02B Beat $1.01B Estimate

Aurora Mobile's SendCloud And SaleSmartly Forge Strategic Alliance To Elevate Global Email Marketing Performance

Evercore ISI Group analyst Daniel Markowitz initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Outperform rating and announces Price Target of $275.

Price Target

Initiation

Analyst Ratings

Evercore ISI Group Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $275

General

Marriott's Subsidiary Ritz-Carlton Hotel Debuts In Suzhou City Near Shanghai

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ABSI

ACXP

ATER

BEKE

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CTRN

ESLT

ETON

FLOC

HUYA

INKT

OABI

OCFT

ORLA

SNDL

SRFM

STNE

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/WSM/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.93 per share, up from $2.72 per share in the year-ago period. Williams-Sonoma projects quarterly revenue of $2.35 billion, compared to $2.28 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 20, 2024, Williams-Sonoma reported better-than-expected third-quarter financial results and approved a $1 billion stock repurchase authorization.
Williams-Sonoma shares rose 4.5% to close at $175.00 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/wsm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Goldman Sachs analyst Kate McShane maintained a Neutral rating and increased the price target from $170 to $224 on Jan. 30, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and raised the price target from $170 to $195 on Jan. 21, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Zachary Fadem maintained an Equal-Weight rating and raised the price target from $165 to $185 on Jan. 6, 2025. This analyst has an accuracy rate of 84%.</li>
<li>Wedbush analyst Seth Basham maintained a Neutral rating and raised the price target from $135 to $175 on Nov. 21, 2024. This analyst has an accuracy rate of 68%.</li>
<li>TD Cowen analyst Max Rakhlenko maintained a Buy rating and boosted the price target from $165 to $195 on Nov. 21, 2024. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying WSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png" alt="" class="wp-image-819195" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

Williams-Sonoma Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) reported quarterly sales of $204.93 million which missed the analyst consensus estimate of $215.25 million by 4.80 percent. This is a 4.89 percent decrease over sales of $215.47 million the same period last year.

Earnings Misses

HUYA Q4 Sales $204.93M Miss $215.25M Estimate

General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) will release its third-quarter financial results, before the <a href="https://www.benzinga.com/quote/GIS/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the company to report quarterly earnings at 96 cents per share, down from $1.17 per share in the year-ago period. General Mills projects quarterly revenue of $4.95 billion, compared to $5.1 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 27, General Mills finalized the sale of its Canadian yogurt division to Sodiaal. The transaction includes the Canadian operations of well-known yogurt brands such as Yoplait and Liberté, as well as a production facility in Saint-Hyacinthe, Québec..
General Mills shares gained 2.3% to close at $60.94 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/gis/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Ken Goldman maintained a Neutral rating and cut the price target from $62 to $60 on March 11, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Jefferies analyst Rob Dickerson maintained a Hold rating and raised the price target from $58 to $62 on March 10, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Piper Sandler analyst Michael Lavery maintained an Overweight rating and cut the price target from $84 to $71 on Feb. 25, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and cut the price target from $64 to $61 on Feb. 19, 2025. This analyst has an accuracy rate of 63%.</li>
<li>B of A Securities analyst Bryan Spillane maintained a Buy rating and slashed the price target from $78 to $70 on Feb. 19, 2025. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying GIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-1024x575.png" alt="" class="wp-image-828877" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Top Wall Street Forecasters Revamp General Mills Price Expectations Ahead Of Q3 Earnings

UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.11 by 56.36 percent. This is a 2357.14 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $124.10 million which beat the analyst consensus estimate of $97.00 million by 27.94 percent. This is a 77.34 percent increase over sales of $69.98 million the same period last year.

Earnings Beats

UP Fintech Holding Q4 Adj $0.17 Beats $0.11 Estimate, Sales $124.10M Beat $97.00M Estimate

Sprinklr Launches Local Data Hosting Solution In Germany Through Collaboration With Google Cloud

NDAQ

Nasdaq And nuam Extend Partnership To Drive Capital Market Integration In Latin America

Nokia Launches Two New 25G PON Fiber Modems Designed To Deliver Mass-Market High-Speed Residential Connectivity

CLVT

Clarivate Joins With AI Company Iprova To Capture, Create And Refine Inventive Concepts With IP Management Software IPfolio

The ongoing downturn in capital markets, precipitated by President Donald Trump's <a href="https://in.benzinga.com/media/25/03/44349466/trump-trade-policy-a-big-headache-for-customers-says-apple-supplier-foxconns-ceo-very-very-hard-to-predict-how-things-will-develop">tariff policies</a>, has eroded a significant chunk of value from entities tied to the president himself.
What happened: Shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), co-founded and <a href="https://in.benzinga.com/25/03/44268596/trumps-net-worth-plummets-by-nearly-300m-as-djt-stock-drops-to-its-lowest-since-october">majority-owned by Trump</a>, have shed 48% of their value since the presidential inauguration. The stock closed at a five-month low of $19.17 last week.
The decline has coincided with a broader stock market selloff, with blue-chip averages like the Dow Jones Industrial Average and the S&amp;P 500, falling 3.7% and 5.3%, respectively, since Trump's White House return.
However, these losses paled in comparison to the hammering Trump's much-hyped Official Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) meme coin has taken in recent weeks.
After <a href="https://www.benzinga.com/25/01/43257114/donald-and-melania-trump-memecoins-defy-market-lull-with-rallyanalyst-says-trump-bottomed-out-at-25">accumulating billions</a> in market value upon launch, TRUMP has lost course.&nbsp;
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363340/crypto-leaders-step-up-pressure-on-sec-as-trumps-policies-reshape-regulatory-landscape">Crypto Leaders Step Up Pressure On SEC As Trump&#8217;s Policies Reshape Regulatory Landscape</a>
The Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based meme coin, whose majority supply is controlled by The Trump Organization, has collapsed 85% from its all-time high set just before Trump's inauguration.
Memecoins, especially those lacking community support and utility, are highly speculative investments, prone to wild swings in short periods. 
While TRUMP was certainly affected more, the risk-on markets suffered the brunt of Trump&#8217;s <a href="https://in.benzinga.com/markets/25/03/44321506/trumps-tariff-policies-a-self-inflicted-wound-says-obama-era-treasury-secretary-larry-summers-economists-weigh-in-as-sp-enters-correction-zone">&#8220;chaotic&#8221; tariff measures</a> against some of America&#8217;s largest trading partners. The situation was compounded when Trump <a href="https://in.benzinga.com/trading-ideas/movers/25/03/44212362/bitcoin-ethereum-and-dogecoin-crash-as-trump-refuses-to-rule-out-recession-arthur-hayes-predicts-btc-to-retest-78000">declined to rule out a potential recession </a>in 2025.
Price Action: At the time of writing, TRUMP was exchanging hands at $10.99, down 2.54% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Shares of IBIT closed 1.73% higher at $20.56 during Monday&#8217;s regular session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. SPY stock gained 2.07% to close at $562.81.
The DJT stock performed poorly in growth rankings—a measure of its historical earnings and revenue growth—but you can find high-growth equities on <a href="https://www.benzinga.com/screener/top-growth-stocks">Benzinga's </a>proprietary Edge Rankings score.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

$TRUMP

TRUMP

DJT Stock Has Plummeted 50% Since Trump's Inauguration But Investors Could Take Heart Its Fate Is Not As Bad As TRUMP Memecoin

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) will release its fourth-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/hqy/earnings">Tuesday, March 18.</a>
Analysts expect the Draper, Utah-based company to report quarterly earnings at 72 cents per share, up from 63 cents per share in the year-ago period. HealthEquity projects quarterly revenue of $305.82 million, compared to $262.39 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 9, 2024, HealthEquity posted mixed results for the third quarter.
HealthEquity shares gained 3.4% to close at $100.72 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barrington Research analyst Alexander Paris maintained an Outperform rating and a price target of $112 on March 14, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Raymond James analyst C. Gregory Peters maintained an Outperform rating and raised the price target from $105 to $120 on Feb. 25, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Mizuho analyst Steven Valiquette initiated coverage on the stock with an Outperform rating and a price target of $126 on Dec. 4, 2024. This analyst has an accuracy rate of 60%.</li>
<li>B of A Securities analyst Allen Lutz maintained a Buy rating and raised the price target from $100 to $120 on Nov. 13, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Deutsche Bank analyst George Hill maintained a Buy rating and increased the price target from $102 to $103 on Sept. 4, 2024. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png" alt="" class="wp-image-828822" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Long Ideas

HealthEquity Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

After several delays, NASA astronauts Butch Wilmore and Sunita Williams have finally begun their journey back to Earth in a SpaceX capsule after an extended stay on the International Space Station (ISS).
What Happened: The astronauts departed early Tuesday morning, concluding a mission that extended far beyond its original timeline—the duo, along with two other astronauts, undocked from the ISS at 1:05 a.m. ET, beginning a 17-hour trip to Earth.
Their return marks the end of a mission initially planned as an eight-day test flight but extended due to technical issues with the Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Starliner spacecraft.
Wilmore and Williams were part of NASA&#8217;s Crew-9 mission, which faced delays after the Starliner&#8217;s propulsion system malfunctioned. This led to NASA&#8217;s decision to bring them back using SpaceX&#8217;s Crew Dragon, the only operational U.S. orbital-class crew spacecraft.
See Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44299887/tsla-stock-may-see-a-significant-upswing-says-jim-cramer-should-be-ready-to-rally-maybe-furiously"> TSLA Stock May See A Significant Upswing, Says Jim Cramer: &#8216;Should Be Ready To Rally, Maybe Furiously&#8217;</a>
The astronauts are expected to splash down off Florida&#8217;s coast at 5:57 p.m. ET. Upon their return, they will undergo health checks at NASA&#8217;s Johnson Space Center in Houston before reuniting with their families.
Wilmore and Williams conducted scientific research and maintenance tasks during their extended stay, including spacewalks. Their mission drew attention from U.S. President Donald Trump, who advocated for their earlier return.
Why It Matters: The return of Wilmore and Williams marks the resolution of a prolonged mission that was initially delayed due to technical issues with the Boeing Starliner spacecraft.
The astronauts were originally scheduled for a brief mission, but their stay was extended to nine months due to the propulsion system malfunction. In response, NASA and SpaceX <a href="https://www.benzinga.com/25/03/44344973/nasa-spacex-one-step-closer-to-bring-back-astronauts-butch-wilmore-sunita-williams-stranded-due-to-boeings-starliner-issues-replacement-crew-launches-successfully">launched</a> a new crew to the ISS to facilitate their return.
Compounding the delay, a hydraulics<a href="https://www.benzinga.com/25/03/44296357/spacex-crew-10-astronaut-launch-to-bring-back-stuck-astronauts-delayed-due-to-hydraulics-issue-says-nasa"> issue</a> with the SpaceX Crew-10 mission further postponed their return. Despite speculation about political influences, Wilmore<a href="https://benzinga.com/25/03/44161444/starliner-astronaut-butch-wilmore-denies-involvement-of-politics-in-delay-in-returning-home-from-space-refuting-spacex-ceo-elon-musk"> clarified</a> that the delay was purely technical.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44354592/warren-buffett-backed-byd-eyes-germany-for-third-european-plant-amid-tariff-concerns-report">Warren Buffett-Backed BYD Eyes Germany For Third European Plant Amid Tariff Concerns: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: NASA

SPACE

NASA Astronauts Sunita Williams And Butch Willmore Head Back To Earth On SpaceX Dragon Capsule

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index surging more than 350 points during the session. All three of the major indices recorded back-to-back gains.
Despite gains recorded on Monday, US stocks recorded losses last week. The Dow dipped around 3.1% to record its worst week since March 2023. The S&amp;P 500 dipped more than 2%, recording its fourth straight losing week.
Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares jumped 30% on Monday after the company announced it received a non-binding proposal from WHP Global to acquire the company for $13 per share in cash. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares gained 9% after the company announced the launch of ERNIE 4.5 and deep-thinking model ERNIE X1.
On the economic data front, U.S. retail sales rose 0.2% month-over-month in February following a revised 1.2% decline in January but down from market expectations of a 0.6% rise. The NY Empire State Manufacturing Index declined 26 points to -20.0 in March, recording the lowest reading since May 2023. The NAHB/Wells Fargo Housing Market Index fell to 39 in March versus a reading of 42 in February.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, energy, and consumer staples stocks recording the biggest gains on Monday. However, consumer discretionary stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 353 points to 41,841.63 on Monday. The S&amp;P 500 rose 0.64% to 5,675.12, while the Nasdaq Composite climbed 0.31% at 17,808.66 during Monday's session.
Investors are awaiting earnings results from IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) , and StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 22.1, the index remained in the &#8220;Extreme Fear&#8221; zone on Monday, versus a prior reading of 20.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

BIDU

CWCO

GETY

SAIC

Dow Jumps 350 Points Following Positive Economic Data: Investor Fear Eases, But Greed Index Remains In 'Extreme Fear' Zone

In a move to tap into the growing artificial intelligence (AI) industry in the U.K.,&nbsp;Oracle Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has pledged&nbsp;to invest $5 billion in&nbsp;the country&nbsp;over the next five years.
What Happened: On Monday, Oracle announced that the investment aims to expand the Oracle Cloud Infrastructure&#8217;s footprint in the U.K. and support the U.K. government&#8217;s drive for AI innovation and adoption.
&#8220;By collaborating with global tech leaders like Oracle, we&#8217;re solidifying the UK&#8217;s position at the forefront of the AI revolution,&#8221; stated Britain's technology minister Peter Kyle in a joint statement.
&#8220;The investment will expand Oracle Cloud Infrastructure&#8217;s footprint in the UK and help the UK government deliver on its vision for AI innovation and adoption,&#8221;&nbsp;stated Oracle.
At present, the UK has the world&#8217;s third-largest AI industry, lagging only behind&nbsp;the United States and China.&nbsp;The Starmer administration estimates that AI could contribute £47 billion ($61 billion) annually to the UK economy over the next decade.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44370144/record-breaking-517-million-bitcoin-short-placed-by-influential-whale-analyst-says-the-investor-isnt-dumb">Record-Breaking $517 Million Bitcoin Short Placed By Influential Whale—Analyst Says The Investor Isn&#8217;t Dumb</a>
Why It Matters: U.K. Prime Minister Keir Starmer is focused on easing regulatory barriers to secure substantial investment to help establish the nation as a leading &#8220;AI superpower.&#8221;
Interestingly, Oracle&#8217;s founder Larry Ellison, who is expected to play a pivotal role in this initiative, is a long-time supporter of U.S. President Donald Trump, and a close friend of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk.
U.K. PM Starmer is in also talks with the Trump administration to reach a post-Brexit trade deal.
This investment comes at a time when Oracle is reportedly in advanced talks with the White House to manage the U.S. operations of the Chinese short video app TikTok, amid <a href="https://www.benzinga.com/25/03/44350823/oracle-reportedly-in-talks-with-white-house-over-project-texas-20-to-manage-tiktok-amid-security-concerns">ongoing concerns</a> about national security. 
The UK&#8217;s strategic push into AI, backed by Oracle&#8217;s investment, could potentially reshape the global AI landscape, positioning the UK as a leading player in this rapidly evolving field.
Oracle stock climbed 3.2% to close at $154.01&nbsp;on Monday, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/politics/25/03/44362774/exclusive-reader-poll-shows-strong-approval-rating-for-president-donald-trumps-first-52-days-in-office-but-theres-a-catch">EXCLUSIVE: Reader Poll Shows Strong Approval Rating For President Donald Trump&#8217;s First 52 Days In Office, But There&#8217;s A Catch</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

ORCL

TSLA

Trump Ally Larry Ellison's Oracle Pledges $5 Billion To Boost UK's AI-Driven Cloud Infrastructure

Prominent Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) investor Ross Gerber has publicly criticized Tesla Board Chair Robyn Denholm, accusing her of neglecting shareholder interests while amassing substantial <a href="https://www.benzinga.com/markets/equities/25/03/44099647/tesla-chair-robyn-denholm-sells-over-30-million-in-shares-as-stock-drops-nearly-3-amid-trump-tariff-concerns">personal wealth from her position</a>.
What Happened: Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, wrote on X Monday: &#8220;Robyn Denholm is the woman paid off to do NOTHING to protect the 83% of Tesla investors she is negligently representing. She only represents one shareholder, Musk.&#8221;
His comments came in response to a Reuters report revealing Denholm&#8217;s compensation since joining the board in 2014 has totaled approximately $682 million in cash and stock. According to the analysis, she has already sold about $532 million worth of Tesla stock.
Reuters described the 61-year-old former accountant as &#8220;the chief defender&#8221; of CEO Elon Musk&#8216;s controversial $56 billion pay package, which has faced legal challenges. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Robyn Denholm is the woman paid off to do NOTHING to protect the 83% of tesla investors she is negligently representing. She only represents one shareholder, Musk. And why… "Her Tesla compensation since she first joined the board in 2014 has totaled about $682 million in cash… <a href="https://t.co/sGnXsfBdln">https://t.co/sGnXsfBdln</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1901771876793504092?ref_src=twsrc%5Etfw">March 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Gerber&#8217;s criticism comes amid broader tensions surrounding Tesla. The company faces mounting protests at showrooms nationwide, triggered by Musk&#8217;s role in President Donald Trump&#8216;s Department of Government Efficiency (DOGE) and his political activities. Gerber himself recently shared <a href="https://www.benzinga.com/markets/equities/25/03/44350195/ross-gerber-shares-peaceful-display-of-distaste-for-elon-musk-in-santa-monica-his-9-year-old-observes-glad-we-dont-have-a-tesla">footage of protesters outside a Tesla store</a> in Santa Monica, concluding with his 9-year-old child saying, &#8220;I&#8217;m glad we don&#8217;t have a Tesla.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/25/03/44369830/jim-chanos-slams-palantir-management-for-continuing-to-ridicule-skeptics-while-executives-sell-328-million-worth-of-stock">Jim Chanos Slams Palantir Management For Continuing To &#8216;Ridicule&#8217; Skeptics While Executives Sell $328 Million Worth Of Stock</a>
Why It Matters: Despite being a long-term investor, Gerber has grown increasingly critical of Tesla, recently stating the shares remain overvalued even after plunging nearly 50% since mid-December. &#8220;There&#8217;s this game that is happening now where the fundamental story has to be revalued,&#8221; Gerber said, noting Tesla&#8217;s forward price-to-earnings ratio remains more than <a href="https://www.benzinga.com/markets/equities/25/03/44350195/ross-gerber-shares-peaceful-display-of-distaste-for-elon-musk-in-santa-monica-his-9-year-old-observes-glad-we-dont-have-a-tesla">triple the S&amp;P 500 average</a>.
The <a href="https://www.benzinga.com/markets/25/03/44346423/teslas-biggest-bull-frustrated-with-elon-musks-focus-on-doge-over-company-patience-wearing-thin">criticism extends beyond Gerber</a>. Wedbush Securities analyst Dan Ives recently remarked that &#8220;Tesla investors are seeing patience wear thin&#8221; regarding Musk&#8217;s divided attention, noting there has been &#8220;little to no sign of Musk at any Tesla factory or manufacturing facility in the last two months.&#8221;
Tesla reported its first-ever annual sales decline in 2024, though Musk pledged Tuesday that Tesla would double its U.S. vehicle production over <a href="https://www.benzinga.com/markets/equities/25/03/44350195/ross-gerber-shares-peaceful-display-of-distaste-for-elon-musk-in-santa-monica-his-9-year-old-observes-glad-we-dont-have-a-tesla">the next two years</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence" target="_blank" rel="noreferrer noopener">Jamie Dimon Cashed Out $234 Million In JPMorgan Stock, Warren Buffett Stockpiled $334 Billion In Cash — Weeks Later, Markets Crashed. Coincidence?</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Short Sellers

Ross Gerber Says Tesla Chair Robyn Denholm Paid Off To Do Nothing:  'Only Represents' Elon Musk While Pocketing $682 Million

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) to report quarterly earnings at 4 cents per share on revenue of $424.00 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. IHS shares gained 0.5% to $3.93 in after-hours trading.</li>
<li>Analysts are expecting HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) to post quarterly earnings at 72 cents per share on revenue of $306.05 million. The company will release earnings after the markets close. HealthEquity shares rose 1.1% to $101.87 in after-hours trading.</li>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) posted upbeat results for its fourth quarter on Monday. Getty Images shares fell 0.9% to $2.1301 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported worse-than-expected fourth-quarter financial results. Sangamo Therapeutics shares fell 3% to $0.98 in the after-hours trading session.</li>
<li>Analysts expect StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) to post quarterly earnings at 35 cents per share on revenue of $647.56 million after the closing bell. StoneCo shares rose 0.1% to $10.20 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

SGMO

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Health Care

Press Releases

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology to Participate in Two Upcoming Investor Conferences

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Comments

Mural Oncology

Mural Oncology (MURA) Opciones

Mural Oncology (NASDAQ:MURA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL